URL : https://gphin.canada.ca/cepr/showarticle.jsp?docId=1006884784
ID : GPHN2020050100189

Date : 2020-05-01 04:03:00
Title : Glenmark Gets DCGI Nod for Clinical Trials of Favipiravir
Ariticle : 
Glenmark Pharmaceuticals on Thursday said that it has received the Drug Controller General of India's approval to conduct clinical trials of anntiviral drug Favipiravir that is being used for Covid-19 treatment in a few countries.
The drug sold under the brand name Avigan by Fujifilm Toyama Chemical has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections.
Following the development, shares of Glenmark jumped by 9% in the exchanges, closing at ?337.
Fujifilm too has started phase 3 trial on this drug and also increased its production. Glenmark's announcement comes at a time when another Indian company, Strides Pharma, said that it has already started shipping the drug to countries in the Gulf region."Having developed the API and the formulations for the product, Glenmark filed the product for clinical trials with DCGI and has received approval for conducting trials on mild to moderate patients," the company said.
As per the clinical trial protocol approved, 150 subjects with mild to moderate Covid-19 will be randomized in the study in a 1:1ratio to Favipiravir with standard supportive care or standalone standard supportive care. Treatment duration is a maximum of 14 days and the total study duration will be maximum for 28 days from randomisation.